Mediastinum Diseases: Myasthenia Gravis
Özet
Referanslar
Cea G, Benatar M, Verdugo RJ, Salinas RA. Thymectomy for non-thymomatous myasthenia gravis. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD008111. DOI: 10.1002/14651858.CD008111.pub2
Binks S, Angela A, Palace J. Myasthenia gravis: a clinical-immunological update. J Neurol. 2016; 263 (4): 826–34
Deymeer F. Nöromuskuler kavşak hastalıkları. Ch: 2, pp 426-439. In: Emre M (editör). Nöroloji temel kitabı 1st , 2013. Güneş tıp kitabevi.
Gwathmey KG, Burns TM. Myasthenia gravis. Semin Neurol 2015;35:327–39.
Tsuchida M, Yamoto Y, Souma T, Yoshiya Katsuo, et al. Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis. Ann Thorac Surg. 1999; 67(6):1563–67.
Evoli A. Myasthenia gravis: new developments in research and treatment. Curr Opin Neurol. 2017, 30:464–70.
Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375:2570-81.
Saruhan-Direskeneli G, Hughes T, Yilmaz V, Durmus H, et al. Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis. Clin Immunol. 2016; 166-167:81–88.
Wong S, Petrie A, Plant G. Ocular MG: towards a risk of generalisation (‘ROG’) score.pp 48 In: Association of British Neurologists (ABN) annual meeting, final programme and abstract book, 2015. Harrogate, UK: ABN.
Oflazer PS, Deymeer F. Kas ve nöromuskuler kavşak hastalıkları. Ch:37, pp 759-77. In: Oge AE, Baykara B ( editors ). Nöroloji 2nd. 2011. Nobel Tıp Kitabevi.
Sanders DB, Wolfe GI, Benatar M, Evoli A, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016; 87: 419-25.
Heckmann J, Rawoot A, Bateman K, Renison R, Badri M. (2011) A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 2011; 5(11):97.
Catzola V, Battaglia A, Buzzonetti A, Fosatti M, et al. Changes in regulatory T-cells after rituximab in two patients with refractory myasthenia gravis. J Neurol. 2013;260(8):2163–65.
Clinical trials.gov. Safety and efficacy of eculizumab in refractory generalized myasthenia gravis (REGAIN study). ClinicalTrials.gov identifier NCT01997229 [on-line]. Web-page last updated 2015 July 6. https://clinicaltrials.gov/ct2/show/ NCT01997229. Accessed 13 Aug 2015.
Bryant A, Atkins H, Pringle CE, et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA. Neurol 2016; 73:652– 58.
Barth D, Nouri NM, Ng E, New P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011; 76: 2017-23.
Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology. 2009; 72: 1548-54.
Gronseth GS, Barohn RJ. Practiceparameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 55: 7-15.
Wolfe GI, Kaminski HJ, Aban IB, Minisman G, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016; 375:511–22.
Luo Y , Pan D, Chen F , Zhu M , et al . Effectiveness of thymectomy in non-thymomatous myasthenia gravis: a systematic review. J Huazhong Univ Sci Technol [Med Sci]. 2014;34(6):942-49.
Werneck LC, Cunha FM, Scola RH. Myasthenia gravis: a retrospective study comparing thymectomy to conservative treatment. Acta Neurol Scand. 2000;101(1):41-46.
Kertya,E, Elsaisa A, Argovc Z, Evolid A, Gilhuse NE. EFNS/ENS guidelines for the treatment of ocular myasthenia. European Journal of Neurology. 2014; 21: 687–93.
Norwood F, Dhanjal M, Hill M, James N, et al. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. J Neurol Neurosurg Psychiatry. 2014; 85: 538-43.
Ferrero S, Pretta S, Nicoletti A, Petrera P, Ragni N. Myasthenia gravis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005; 121: 129-38.
Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol. 2007; 14: 38-43.
